PRESS RELEASE: FILAMENT HEALTH ANNOUNCES CHANGE TO BOARD OF DIRECTORS

10 months ago

VANCOUVER, BC , May 3, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical-stage natural psychedelic drug development company, today announced that Chris Wagner has stepped down from his position as Director on the Company’s board of directors due to the requirements of a new role, effective April 30, 2024. Wagner commented: “I […]